Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Centre of Excellence at Kharel comprises Skill-building Centre and Primary, Secondary and Higher Secondary schools
New Director supports NASDAQ rule on diversity
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
Company hires life science veteran Jessica Cao to join management team
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
Subscribe To Our Newsletter & Stay Updated
